Cannabinoids for Behavioral Symptoms in Dementia: An Overview
Source : https://pubmed.ncbi.nlm.nih.gov/38447959/
Dementia, with loss of memory, cognitive abilities, and independent daily functioning, is increasing worldwide, related to an aging population. Currently, there is no curative treatment for dementia. Treatment of the...
Recent trials suggest THC/CBD-based medications show promise for managing BPSD in dementia, with higher doses proving feasible and safe. Ongoing research aims to refine dosing, efficacy, and broader impacts.
Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease: Systematic review and meta-analysis
Source : https://pubmed.ncbi.nlm.nih.gov/38968479/
Our results suggested that olanzapine might be statistically superior to risperidone on the reduction of BPSD of Alzheimer's disease, especially in the relief of delusions and nighttime behavior disturbances. In...
Our results suggested that olanzapine might be statistically superior to risperidone on the reduction of BPSD of Alzheimer's disease, especially in the relief of delusions and nighttime behavior disturbances. In addition, olanzapine was shown statistically lower risks of agitation, sleep disturbance, and extrapyramidal signs.
Guideline Recommendations on Behavioral and Psychological Symptoms of Dementia: A Systematic Review
Source : https://pubmed.ncbi.nlm.nih.gov/38640961/
There are several moderate to high-quality clinical practice guidelines making recommendations on BPSD assessment and management, but variability in recommendation statements across guidelines and insufficient consideration of guideline applicability may...
There are several moderate to high-quality clinical practice guidelines making recommendations on BPSD assessment and management, but variability in recommendation statements across guidelines and insufficient consideration of guideline applicability may hamper guideline dissemination and implementation in clinical practice.
Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease
Source : https://pubmed.ncbi.nlm.nih.gov/38791206/
Dementia exists as a 'progressive clinical syndrome of deteriorating mental function significant enough to interfere with activities of daily living', with the most prevalent type of dementia being Alzheimer's disease...
While current treatments for Alzheimer's disease focus on symptom management, including amyloid-β-targeting drugs, they offer limited efficacy and do not address associated neuropsychiatric symptoms like anxiety. There is a critical need for innovative therapies targeting these symptoms to enhance patient care and quality of life.
Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial
Source : https://pubmed.ncbi.nlm.nih.gov/38849944/
Approved by Western Institutional Review Board on 12/31/2017 (#20172897) and by Institutional Review Boards of all sites. This study was registered retrospectively with clinicaltrials.gov on October 8, 2020 (NCT04606420, ID:...
Comprehensive lifestyle changes may significantly improve cognition and function after 20 weeks in many patients with MCI or early dementia due to AD.